Healthcare & Pharma
Last Updated: 21 April 2026
Oxford Biomedica plc (LSE: OXB) is a leading viral vector contract development and manufacturing organisation (CDMO) specialising in lentiviral and adeno-associated virus (AAV) vectors for cell and gene therapies. The company has transformed from a clinical-stage biotech into a pure-play CDMO and achieved its first full-year operating EBITDA profit in FY2025 (£8.1m) on revenue of £170.9m (+33% YoY). With a revenue backlog of £204m, contracted client orders of £224m and FY2026 guidance of £220–240m, Oxford Biomedica is scaling into a market projected to grow from ~$4bn in 2025 to $10bn by 2031. In April 2026, OXB launched its Fast-Track viral vector development service, cutting industry-standard lentiviral development timelines from 12–18 months to as little as nine months. This report covers every material angle. No analyst opinions or price targets. For live pricing see our live charts, upcoming releases on the economic calendar, and discussion on the ChartsView forum.
<\!-- TradingView Advanced Chart -->1. Company Snapshot
| Field | Value |
|---|---|
| Company | Oxford Biomedica plc |
| Ticker / Exchange | OXB / LSE (AIM graduated to Main Market) |
| Sector (ChartsView) | Healthcare & Pharma — Gene & Cell Therapy CDMO |
| GICS classification | Health Care / Life Sciences Tools & Services |
| Headquarters | Windrush Court, Transport Way, Oxford, OX4 6LT, UK |
| Chief Executive Officer | Dr Frank Mathias (since March 2023) |
| CFO | Stuart Paynter |
| Chairman | Dr Frédéric Roch Doliveux (since 2020) |
| Founded | 1995 (Oxford University spin-out by Prof. Alan Kingsman and Dr Susan Kingsman) |
| Employees | ~1,000 worldwide |
| Fiscal year end | 31 December |
| FY2025 revenue | £170.9m (+33% YoY at constant currency) |
| FY2025 operating EBITDA | £8.1m (first full-year profit since CDMO refocus) |
| FY2025 net loss | ~£37m (IFRS, including non-cash items) |
| Revenue backlog (31 Dec 2025) | ~£204m (+36% YoY) |
| Contracted client orders | £224m (+20% YoY) |
| FY2026 revenue guidance | £220–240m (constant currency) |
| FY2026 EBITDA margin guidance | ~10% full-year (H1 expected EBITDA-negative due to maintenance/integration) |
| Medium-term targets | 25–30% revenue growth p.a. 2027–28; ≥20% EBITDA margin by 2027 |
| Late-stage + commercial programs | 8 (as of March 2026, up from 6 in FY2025) |
| Shares outstanding | ~120.9m |
| Market cap (April 2026) | ~£750m |
| Website | oxb.com |
2. Bull Case vs Bear Case
Distilled from the full report below — factual only, no ratings.
Bull Case
- Structural growth market: The viral vector CDMO market is projected to grow from ~$4bn (2025) to ~$10bn by 2031 as gene and cell therapies move from clinical to commercial. Approximately 75% of production is outsourced to CDMOs like OXB.
- Revenue inflection confirmed: Revenue has nearly doubled from ~£90m (2023) to £170.9m (2025), growing at ~30% CAGR and significantly outpacing the 12% market CAGR.
- First EBITDA profit: FY2025 operating EBITDA of £8.1m marks the inflection to profitability. FY2026 targets ~10% margin with a path to ≥20% by 2027.
- BMS commercial supply agreement: New multi-year commercial supply agreement with Bristol Myers Squibb for lentiviral vector manufacture for CAR-T programmes, announced February 2026. Commercial manufacturing to start in 2026.
- Pipeline deepening: Late-stage and commercial programs rose from 5 (FY2024) to 8 (March 2026). At least one is expected to reach commercial launch in 2026, with additional programs following. Each commercial launch represents recurring, high-margin manufacturing revenue.
- AAV expansion: AAV opportunities have surpassed lentiviral for the first time in OXB’s pipeline (43% AAV vs 40% lentiviral), broadening the addressable market beyond CAR-T.
- US manufacturing footprint: Acquisition of FDA-approved Durham (NC) facility gives OXB end-to-end US manufacturing, critical for US-domiciled pharma clients and regulatory proximity.
- Fast-Track platform: April 2026 launch cuts lentiviral development timelines by up to 50% (from 12–18 months to ~9 months), a significant competitive differentiator for clients racing to IND filings.
- Revenue visibility: ~60% of FY2026 guidance covered by contracted orders; >80% including risk-adjusted pipeline.
Bear Case
- Still IFRS loss-making: Despite EBITDA profit, the company reported a net loss of ~£37m in FY2025 on an IFRS basis, reflecting depreciation, amortisation and financing costs.
- High leverage: Debt-to-equity ratio ~112%; new $100m debt facility plus £60m equity placement in 2025 addressed immediate needs but balance sheet remains stretched.
- Dilution history: Share count has grown from ~80m to ~121m over the last five years through equity raises. Further dilution is possible if growth capex requires additional funding.
- Client concentration: BMS (via Novartis-legacy CAR-T manufacturing) and a small number of major pharma clients represent a significant portion of revenue. Loss of a major client would be material.
- H1 2026 EBITDA-negative: Management has guided that H1 will be EBITDA-negative due to scheduled maintenance shutdowns, technology transfers and Durham facility integration, creating a lumpy earnings profile.
- Competitive intensity: Lonza, Thermo Fisher, Catalent/Novo Holdings, Fujifilm Diosynth and WuXi have greater scale and broader service offerings. Pricing pressure is possible as large CDMOs invest in viral vector capacity.
- Regulatory risk: Gene therapy manufacturing is highly regulated. Any GMP failure, product contamination or regulatory hold could damage client relationships and revenue.
- Clinical trial dependency: Revenue ultimately depends on clients’ clinical trial success. Program cancellations or clinical holds directly reduce manufacturing demand.
- Valuation: At ~£750m market cap on £170m revenue, the stock is priced for significant growth execution. Forward P/E is very high (~200x+ trailing) given losses; the business must grow into its valuation.
3. What Does Oxford Biomedica Actually Do?
Oxford Biomedica is a pure-play viral vector CDMO — it manufactures the delivery vehicles (viral vectors) that gene and cell therapy companies need to get their therapeutic genes into patient cells. The company specialises in two vector platforms: lentiviral vectors (used in CAR-T cell therapies like Novartis/BMS’s Kymriah) and adeno-associated viral (AAV) vectors (used in gene therapies for genetic diseases, eye conditions and neurological disorders).
Revenue by service type (FY2025, approximate):
| Segment | % of revenue | What it is |
|---|---|---|
| Process development | ~40–50% | Designing and optimising viral vector manufacturing processes for clients at preclinical/Phase I; time-limited project fees |
| Clinical GMP manufacturing | ~40–50% | Batch manufacture of lentiviral/AAV vectors to GMP standard for Phase II–III clinical trials; milestone and batch-fee model |
| Commercial manufacturing | ~5–10% | Large-scale ongoing manufacture for 8 approved/late-stage programmes on OXB’s platform; recurring revenue as programmes progress |
Vector type mix (Jan 2026 pipeline view): 43% AAV, 40% lentiviral, 17% other. This marks the first time AAV has exceeded lentiviral in OXB’s pipeline, reflecting the company’s successful expansion beyond its lentiviral heritage.
Geographic footprint. Oxford, UK (headquarters and primary manufacturing campus — multiple GMP suites); Durham, North Carolina, USA (FDA-approved commercial-scale facility acquired 2024/25, providing end-to-end US manufacturing). The dual UK/US footprint is strategically important given that the majority of gene therapy sponsors are US-domiciled.
4. The Business Model
How they make money. OXB earns revenue through a combination of:
- Service fees — Process development, technology transfer and GMP manufacturing under client contracts. Revenue is recognised as performance obligations are met.
- Batch-based manufacturing — Each GMP batch manufactured for a clinical trial or commercial product generates revenue. As programs progress to later stages and commercial launch, batch volumes and revenue per program increase.
- Licensing / royalties — OXB’s proprietary LentiVector® platform generates milestone and royalty income when client products using the platform achieve regulatory or commercial milestones.
Unit economics. FY2025 operating EBITDA margin was ~4.7% (£8.1m on £170.9m revenue) — the first positive year since the CDMO pivot. Management targets ≥20% EBITDA margin by 2027, driven by operating leverage (fixed-cost manufacturing suites generating higher utilisation), the shift toward higher-value commercial manufacturing, and Durham facility integration.
Moat. Oxford Biomedica’s competitive advantages include: (a) 30 years of lentiviral vector expertise originating from the University of Oxford, including the proprietary LentiVector® platform; (b) one of the largest dedicated lentiviral GMP manufacturing capacities globally; (c) expanding AAV capability; (d) dual UK/US manufacturing footprint with FDA-approved commercial facilities; (e) long-term relationships with tier-one pharma (BMS, and undisclosed major clients); (f) the new Fast-Track platform cutting development timelines by up to 50%.
Revenue visibility. Revenue backlog of £204m at end-2025 (+36%) and contracted client orders of £224m provide ~60% coverage of FY2026 guidance, rising to >80% including risk-adjusted pipeline. This is strong visibility for a CDMO business.
5. Financial Health
5-year trend (fiscal years ending 31 December; GBP millions).
| Year | Revenue | YoY % | Op EBITDA | IFRS net income | Cash & equivalents |
|---|---|---|---|---|---|
| 2021 | £128m | +53% | n/a (pre-CDMO pivot reporting) | £11m | ~£100m |
| 2022 | £113m | −12% | n/a | −£36m | ~£83m |
| 2023 | £89.5m | −21% | −£15m (est.) | −£62m | ~£45m |
| 2024 | £128.8m | +44% | −£4m (est.) | −£52m | ~£50m |
| 2025 | £170.9m | +33% | £8.1m | −£37m | ~£54m |
Note: 2021–2022 revenue included significant COVID-19 vaccine manufacturing revenue (AstraZeneca). The dip in 2022–2023 reflects the wind-down of vaccine contracts and transition to pure CDMO operations. The growth trajectory since 2023 represents organic CDMO business only.
Balance sheet. Cash of ~£54m at end-2025. Total debt includes a new $100m facility and existing obligations; debt-to-equity ratio ~112%. An equity placement of £60m in 2025 bolstered the balance sheet. Net debt (enterprise value minus market cap) implies ~£50m net debt. Capex guidance is ~£50m for 2026–27 to support Durham integration and Oxford site expansion. Analysts expect the company to turn net-profit positive in FY2026 (est. ~£12m).
6. Valuation & Market Data
Raw metrics, mid-April 2026. Not opinions on whether the stock is cheap or expensive.
| Metric | Value |
|---|---|
| Share price (LSE, 21 Apr 2026, approx.) | ~620–630p |
| 52-week range | ~270p – 950p |
| Market cap | ~£750m |
| Enterprise value | ~£795m |
| Trailing P/E (GAAP) | n/m (net loss) |
| P/E (forward) | ~60–65x (on estimated £12m net profit) |
| P/S (TTM) | ~4.4x |
| EV/Revenue (trailing) | ~4.7x |
| EV/Revenue (FY2026e, at £230m midpoint) | ~3.5x |
| EV/EBITDA (FY2025) | ~98x (on £8.1m EBITDA) |
| EV/EBITDA (FY2026e, at ~10% margin) | ~34x |
| Dividend yield | Nil (no dividend) |
| Shares outstanding | ~120.9m |
| Analyst consensus target | ~882p (for reference only; not endorsed) |
7. What Are They Building / What’s Coming?
Fast-Track platform (April 2026). Launched 13 April 2026: an expedited development and manufacturing offering that cuts lentiviral vector development from the industry-standard 12–18 months to as little as 9 months, and offers similar acceleration for AAV vectors. This targets clients racing to IND filings and is a significant competitive differentiator.
Durham (NC) facility integration. The FDA-approved commercial-scale facility acquired in 2024/25 gives OXB an end-to-end US manufacturing footprint. Integration is ongoing through H1 2026 (contributing to H1 EBITDA drag). Once fully operational, Durham approximately doubles OXB’s commercial manufacturing capacity and reduces regulatory friction for US-domiciled clients.
AAV platform expansion. OXB has successfully expanded from its lentiviral heritage into AAV vectors, with AAV now representing 43% of the pipeline (vs 40% lentiviral). This is critical because AAV-based gene therapies (for genetic diseases, ophthalmology, neurology) represent a larger addressable market than lentiviral-based CAR-T.
BMS commercial supply agreement. New multi-year agreement announced February 2026 for lentiviral vector manufacture for BMS’s CAR-T programmes (including Kymriah legacy). Commercial manufacturing expected to start in 2026. This deepens OXB’s relationship with its largest historical client.
Pipeline progression. Late-stage plus commercial programs rose from 5 (2024) to 8 (March 2026). At least one program is expected to achieve commercial launch in 2026. Each commercial launch converts from project-based to recurring batch manufacturing revenue with higher margins.
Oxford campus expansion. Continued investment in GMP suite capacity and process development laboratories at the Oxford headquarters, funded from the ~£50m/year capex envelope.
Proprietary LentiVector® platform. OXB’s proprietary technology platform generates milestones and royalties when client products using the platform achieve regulatory approvals. This creates an option-value revenue stream that scales with the cell and gene therapy market.
8. Competitive Landscape
The viral vector CDMO market is moderately fragmented. Large diversified CDMOs compete with specialist players. OXB holds approximately 6% market share in a market growing at ~12% CAGR.
| Competitor | Ticker / exchange | Revenue (latest) | Stronghold | Key overlap with OXB |
|---|---|---|---|---|
| Lonza Group | LONN / SIX | ~CHF 7.5bn (group) | Biologics CDMO (mAb, ADC, viral vectors); largest scale | Viral vector manufacturing at all scales; established commercial manufacturing for approved gene therapies |
| Thermo Fisher (Patheon) | TMO / NYSE | ~$43bn (group) | End-to-end pharma services inc. viral vector manufacturing | Cell therapy / viral vector CDMO services as part of broader biologics and drug product offering |
| Catalent (Novo Holdings) | Private (acq. 2024) | ~$4bn (pre-acquisition) | Drug delivery, biologics, cell & gene therapy manufacturing | AAV and lentiviral vector manufacturing; large-scale commercial capacity |
| Fujifilm Diosynth | Subsidiary of 4901.T | N/A | Process development, viral vector, gene therapy manufacturing | Growing viral vector capacity; recently expanded US and European facilities |
| WuXi Advanced Therapies | 2269.HK / WuXi group | N/A | Cell & gene therapy CDMO; cost-competitive | Lentiviral and AAV vector manufacturing at scale; US + China dual footprint |
| Charles River Labs | CRL / NYSE | ~$4bn (group) | Discovery-to-commercial CRO/CDMO; acquired Vigene Biosciences | AAV viral vector services; upstream process development |
Competitive colour: OXB differentiates as a mid-tier specialist with 30 years of lentiviral expertise, proprietary LentiVector® technology and a strong European manufacturing base now complemented by US capacity. The large diversified CDMOs (Lonza, Thermo Fisher) offer broader service portfolios but less vector-specific depth. WuXi is cost-competitive but faces geopolitical headwinds (US BIOSECURE Act concerns). The Fast-Track platform launched in April 2026 is OXB’s latest move to differentiate on speed.
9. Leadership and Ownership
Dr Frank Mathias has been CEO since March 2023. He previously led Rentschler Biopharma SE as CEO, transforming it into a leading global full-service CDMO, and before that served as CEO of Medigene AG (listed immuno-oncology company). His appointment marked OXB’s definitive pivot to pure-play CDMO operations.
Key executives (April 2026):
- Dr Frank Mathias — Chief Executive Officer
- Stuart Paynter — Chief Financial Officer
- Lisa James — Chief People Officer
- John Foy — Site Head, Durham Operations (joined January 2026)
- Dr Frédéric Roch Doliveux — Chairman of the Board (since 2020)
Ownership. Institutionally held. Major shareholders include Novo Holdings (significant stake via various funds), Baillie Gifford, and other UK/European institutional investors. Free float is high. No single shareholder holds a controlling position.
Insider transactions. Director dealings have been limited to routine share plan vestings. CEO Frank Mathias holds shares acquired via the company share plan. No material discretionary insider purchases or sales have been disclosed in the last 90 days.
<\!-- TradingView Technical Analysis Gauge -->Source: RNS director/PDMR dealings filings, 12 months to April 2026. Oxford Biomedica PDMRs file under UK MAR Article 19. Insider activity in the window was limited — the company underwent a strategic reset and leadership changes during 2024–2025. No material open-market discretionary purchases by continuing directors were reported; new NED appointments included initial qualifying shareholdings at appointment which are disclosed via RNS.
| Name | Date | Type | Shares | Price | Value | Plan Type |
|---|---|---|---|---|---|---|
| No reportable open-market dealings | 12 months to Apr 2026 | — | — | — | — | See regulatory note above |
10. Risks and Challenges
- Profitability not yet proven at scale: FY2025 EBITDA of £8.1m is the first positive year. H1 2026 is guided EBITDA-negative. The path to ≥20% margins by 2027 requires flawless execution on Durham integration, client ramp-ups and operating leverage.
- Balance sheet leverage: Debt-to-equity ~112% is elevated for a company not yet consistently profitable on an IFRS basis. The $100m facility and £60m equity raise provide runway, but further fundraising cannot be ruled out.
- Dilution risk: Share count has grown from ~80m to ~121m over five years. Further equity issuance to fund growth capex or working capital is a possibility that would dilute existing shareholders.
- Client concentration: BMS and a small number of major pharma clients dominate revenue. Loss of a key client contract, clinical trial failure or strategic reprioritisation by a major client would materially impact revenue.
- Clinical trial dependency: OXB’s revenue depends on its clients’ clinical success. Program cancellations, FDA clinical holds or adverse trial results reduce manufacturing demand. OXB does not control this risk.
- Competitive intensity: Lonza, Thermo Fisher, Catalent and Fujifilm are investing heavily in viral vector capacity. Pricing pressure is possible as supply catches up with demand. WuXi offers cost-competitive alternatives.
- Regulatory / GMP risk: Any manufacturing failure, contamination event or regulatory citation at the Oxford or Durham facilities could halt production and damage client trust.
- Technology platform risk: Gene therapy is evolving rapidly. Non-viral delivery methods (lipid nanoparticles for gene editing) could eventually reduce demand for viral vectors, though this is a long-term risk.
- Currency exposure: Revenue increasingly includes USD-denominated contracts (Durham, US clients) while the cost base is partly GBP. GBP/USD movements affect reported results.
- Valuation priced for growth: At ~4.4x P/S and ~34x FY2026e EV/EBITDA, the stock is priced for continued high-growth execution. Any guidance miss would likely result in significant share-price downside.
11. Recent Developments
- Last 48 hours (to 21 April 2026):
- 20 Apr 2026 — OXB shares gap up at market open on continued positive sentiment following the Fast-Track platform launch and BMS commercial supply agreement momentum.
- Last 2 weeks:
- 13 Apr 2026 — Fast-Track viral vector development service launched. Cuts lentiviral development timelines from 12–18 months to as little as 9 months; similar acceleration for AAV. Targets clients racing to IND filings.
- Last 6 months:
- 26 Mar 2026 — FY2025 preliminary results: revenue £170.9m (+33%), first full-year operating EBITDA profit of £8.1m. Backlog £204m (+36%). New FY2026 guidance: £220–240m revenue, ~10% EBITDA margin. Medium-term targets: 25–30% growth, ≥20% EBITDA margin by 2027.
- Feb 2026 — New multi-year Commercial Supply Agreement with BMS for lentiviral vector manufacture for CAR-T programmes. Commercial manufacturing to start in 2026.
- Jan 2026 — John Foy joined as Site Head, Durham Operations, strengthening US leadership.
- Jan 2026 — Pipeline update: AAV opportunities (43%) surpassed lentiviral (40%) for the first time. Late-stage + commercial programs at 8.
- Sep 2025 — H1 2025 interim results: revenue £78.4m (+29%); H1 on track for full-year guidance. Confirmed medium-term 35%+ revenue CAGR target (2023–2026).
12. Key Dates Coming Up
- 7 May 2026 — Annual General Meeting (Oxford).
- H1 2026 — BMS commercial manufacturing expected to begin under new supply agreement.
- Sep 2026 (est.) — H1 2026 interim results.
- 2026 — At least one client program expected to achieve commercial launch, triggering recurring commercial manufacturing revenue.
- Mar 2027 (est.) — FY2026 preliminary results.
- 2027 — Target year for ≥20% operating EBITDA margin.
Related pages: Live charts | Economic calendar | ChartsView forum | Blog
Disclaimer: This research is for information only and is not investment advice or a recommendation to buy or sell any security. All figures are sourced from Oxford Biomedica filings, RNS announcements, and public market data as at the date above. Forward-looking statements are attributed to the company and may not be achieved. Always do your own research.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.
Last Updated: 19 April 2026
Hims & Hers Health (NYSE: HIMS) is the largest direct-to-consumer telehealth platform in the US, with 2.51 million subscribers and $2.35 billion in FY2025 revenue. The business model — subscription telehealth with vertically integrated compounding pharmacies — has been shaken in the last 90 days by the FDA's tightening stance on compounded GLP-1 medicines, a short-lived patent lawsuit from Novo Nordisk, and a DOJ referral. It has also been boosted by a mid-March settlement that turned Novo from plaintiff into distribution partner, and a surprise 16 April announcement from RFK Jr. that the FDA will review removing 12 peptides from compounding restrictions. This report walks through the numbers, the moat, the risks and every material development in the last six months.
1. Company Snapshot
| Item | Detail |
|---|---|
| Full name | Hims & Hers Health, Inc. |
| Ticker | NYSE: HIMS |
| Sector / Industry | Healthcare / Telehealth & Digital Health |
| Founded | 2017 (Public via SPAC, January 2021) |
| Headquarters | San Francisco, California, USA |
| CEO | Andrew Dudum (Co-Founder) |
| Market cap (19 April 2026) | ~$6.57 billion |
| Share price | ~$28.66 |
| Revenue (FY2025) | $2,347.6 million (+59% YoY) |
| Net income (FY2025) | $128.4 million |
| Employees | ~5,000+ |
| Exchange | NYSE (primary) |
| Website | hims.com |
2. Bull Case vs Bear Case
Bull Case
- Scale and growth. Largest US D2C telehealth platform, 2.51m subscribers (+13% YoY), $2.35bn FY25 revenue (+59% YoY). Multi-condition subscribers grew 80% YoY and now exceed 20% of the base.
- Vertical integration. Owns MedisourceRx (503B compounding), Trybe Labs (at-home testing), peptide manufacturing (former CS Bio assets). Supply chain control enables higher gross margins than a pure referral model.
- Novo Nordisk partnership. March 2026 settlement made Hims a preferred D2C distributor of branded Wegovy and Ozempic; CEO Dudum has publicly stated the company is "on track to deliver over 100,000 Wegovy prescriptions per month."
- Peptide optionality. On 16 April 2026, HHS/FDA announced a July 2026 advisory review of removing 12 peptides (BPC-157, TB-500, semax, epitalon, others) from Category 2 restrictions. If reclassified, Hims can legally compound them — repurposing existing manufacturing capacity into new high-margin categories.
- Profitable with growing international footprint. FY25 adjusted EBITDA $318m (13.5% margin). Acquisitions of ZAVA (UK, Germany, France, Ireland) and Livewell (Canada) drove international revenue +400% to ~$134m.
Bear Case
- FDA compounding crackdown. May 2025 ended the semaglutide shortage exemption. In February 2026 the FDA forced Hims to withdraw its $49 compounded oral semaglutide pill within 48 hours and HHS referred the company to the DOJ. Compounded margins are structurally at risk.
- Gross margin compression. Gross margin fell from 79% in FY24 to 74% in FY25. The Novo partnership distributes branded drugs at ~25–35% gross margin vs 60–70% on compounded alternatives. Q1 2026 guidance carries a ~$65m weight loss timing headwind.
- Active DOJ and SEC attention. DOJ referral remains open; SEC probing disclosures. Outcomes unknown; legal costs and reputational damage are live.
- Subscriber growth decelerating. 13% subscriber growth in 2025 is well below broader telehealth (20–30% CAGR). Weight loss economics are being reset.
- Leverage up sharply. Total debt rose to ~$971m in 2025 (from ~$150m) after a $1.0bn convertible senior note issuance in May 2025. Debt-to-equity ~1.8x; dilution risk on the convert is real.
3. What Does This Company Actually Do?
Hims & Hers runs a direct-to-consumer telehealth subscription platform. A customer completes an online intake, is matched with a licensed clinician, gets a prescription (where appropriate), and receives the medication on recurring delivery. Over time the company has built — or bought — the pieces of the stack, including the compounding pharmacy that makes many of the medicines.
| Segment | % of revenue | What it is |
|---|---|---|
| Online Revenue | ~98.4% (~$2,310m) | D2C subscriptions on the Hims and Hers platforms |
| Wholesale Revenue | ~1.6% (~$38m) | B2B health plan and pharmacy partnerships |
By product category the mix is roughly weight loss ~31%, sexual health (Hims) ~30%, women's health (Hers) ~30%, mental health, dermatology and hormonal health (new low-T and menopause lines launched in 2025). Customers are almost entirely B2C consumers in the US, Canada, UK, Germany, France and Ireland.
4. The Business Model
Revenue is recurring subscription, and the moat sits in three places: (1) brand and scale — Hims/Hers is one of the most recognised consumer health brands in the US, with 2.5m paying subscribers; (2) vertical integration — owning the compounding pharmacy (MedisourceRx 503B), peptide manufacturing (former CS Bio facility) and at-home lab testing (Trybe Labs); (3) data and personalization — 50% YoY growth in personalized-plan subscribers, with multi-condition users (80% YoY growth) generating substantially higher lifetime value.
| Margin metric | FY2025 | FY2024 |
|---|---|---|
| Gross margin | 74% | 79% |
| Operating margin | 4.5% | 4.2% |
| Net profit margin | 5.5% | 8.5% |
| Adjusted EBITDA margin | 13.5% | ~10.8% |
Subsidy / regulatory credit dependency. Hims does not receive direct government subsidies. However, its compounded-drug margin structure depends on regulatory permission to compound medicines under FDA rules (503A and 503B). When the FDA declared the semaglutide shortage over in May 2025 it removed the legal basis for mass-market compounding of semaglutide; this is functionally a negative regulatory-credit event. The reverse — de-restriction of 12 peptides under review in July 2026 — would be a positive one. This regulatory exposure is the single most important thing to understand about the business model.
5. Financial Health
| Year | Revenue | Net income | YoY revenue |
|---|---|---|---|
| 2020 | $52.7m | -$13.4m | — |
| 2021 | $152.4m | -$29.9m | +189% |
| 2022 | $594.9m | -$22.4m | +290% |
| 2023 | $926.3m | $51.2m | +56% |
| 2024 | $1,476.5m | $126.0m | +59% |
| 2025 | $2,347.6m | $128.4m | +59% |
| Cash & balance sheet (year-end 2025) | Amount |
|---|---|
| Operating cash flow (FY25) | $300.0m |
| Free cash flow (FY25) | $57.4m |
| Capex (FY25) | ~$242.6m (+232% YoY) |
| Cash & equivalents | $578m |
| Short-term investments | $51.7m |
| Long-term investments | $351m |
| Total debt | $971m (incl. $1.0bn convertible notes due 2030) |
| Net debt | ~$393m |
| Principal liquidity | ~$929m |
FCF fell year-over-year despite higher operating cash flow, because capex tripled. No dividend. Share count has grown with equity comp and the May 2025 convertible note.
6. Valuation & Market Data
Figures below sourced from public filings and market data providers as of 19 April 2026. Intraday numbers change — use the ChartsView live charts for the current price.
| Metric | Value |
|---|---|
| Share price | ~$28.66 |
| Market cap | ~$6.57bn |
| Enterprise value | ~$6.37bn |
| Trailing P/E (GAAP) | ~30–56x (varies by source) |
| P/E (forward) | ~52x |
| P/S (TTM) | ~2.8x |
| EV/EBITDA (on FY25 adj EBITDA) | ~40x |
| EV/FCF | ~96x (capex distorted) |
| 52-week high | $70.43 (19 Feb 2025) |
| 52-week low | $13.74 (27 Feb 2026) |
| Short interest (shares) | 71.36m |
| Short interest (% of float) | ~31.3% |
| Days to cover | ~2.5 |
| Short interest report date | 31 March 2026 |
Short interest is very high — over 30% of float — though days-to-cover is only a couple of days given the stock's high daily turnover.
7. What Are They Building / What's Coming?
GLP-1 — from compounding to distribution
After the FDA declared the semaglutide shortage over in May 2025 and forced a pullback of Hims' compounded oral semaglutide pill in February 2026, the company settled the Novo Nordisk patent lawsuit on 9 March 2026. Under the settlement, Hims distributes branded Wegovy and Ozempic at comparable pricing to other telehealth platforms. CEO Dudum stated publicly the company is "on track to deliver over 100,000 Wegovy prescriptions per month." Hims has ceased mass-marketing of compounded GLP-1 alternatives.
Peptide optionality (catalyst: 23–24 July 2026)
On 16 April 2026 HHS Secretary Robert F. Kennedy Jr. announced the FDA will convene a Pharmacy Compounding Advisory Committee on 23–24 July 2026 to review removing 12 peptides — including BPC-157, KPV, TB-500, MOTs-C, semax and epitalon — from Category 2 restrictions. If reclassified, Hims could compound and distribute them at scale. The stock rose 13.7% on the day of the announcement.
New categories launched 2025–2026
- Low testosterone. Compounded enclomiphene + tadalafil launched Q3 2025; exclusive partnership with Marius Pharmaceuticals for branded oral testosterone (KYZATREX) in 2026.
- Menopause / perimenopause. Hers specialty launched Q4 2025, with a stated target of $1bn of Hers revenue in 2026 (vs ~$700m in 2025).
- At-home diagnostics. Trybe Labs (acquired Feb 2025) integrating through 2026.
International
ZAVA (UK, Germany, France, Ireland — announced June 2025) and Livewell (Canada) added a combined ~1.3m European customers; international revenue grew ~400% YoY to ~$134m in 2025.
Management guidance (from the 23 February 2026 earnings call)
- Full year 2026 revenue $2.7–2.9bn (mid-point +19% YoY)
- Adjusted EBITDA $300–375m
- Q1 2026 revenue $600–625m; Adj EBITDA $35–55m — includes a ~$65m timing drag from weight-loss shipping cadence changes plus Super Bowl ad spend
8. Competitive Landscape
| Competitor | Position | Notes |
|---|---|---|
| Ro Pharmacy | Private D2C telehealth | Aggressive unit economics; similar multi-category playbook |
| LifeMD (LFMD) | Public D2C telehealth | ~500k subscribers; had a Novo Nordisk partnership that was scaled back in 2025 |
| Teladoc (TDOC) | B2B / enterprise telehealth | Different customer mix; less direct D2C competitor |
| Novo Nordisk | Branded GLP-1 | Now Hims' partner on Wegovy/Ozempic distribution |
| Eli Lilly | Branded tirzepatide | Zepbound/Mounjaro, not on the Hims platform as of April 2026 |
| CVS / Walgreens / Amazon Pharmacy | Retail pharmacy + telehealth | Growing digital-prescription capabilities |
Policy impact analysis. The FDA's May 2025 end of the semaglutide shortage was a symmetric shock — it hit Hims, Ro, LifeMD and independent compounders. Hims has the deepest compounding infrastructure (MedisourceRx, peptide facility) and the biggest brand, but it also has the most to lose by unit volume in weight loss. Novo and Lilly benefited: branded-only distribution post-shortage is worth more. If the July 2026 peptide advisory goes Hims' way, it would reopen a compounding edge that's hard to replicate quickly — favouring the player with owned 503B capacity.
9. Leadership and Ownership
Andrew Dudum co-founded Hims in 2017 and has been CEO since. Background: Wharton, Atomic Labs, early-stage consumer investor. Hilary Coles co-founded the business and leads the Hers brand. Yemi Okupe is CFO, with prior finance roles at Uber, eBay, PayPal and Google. Nader Kabbani was appointed COO in May 2025.
Ownership. Institutional ownership is approximately 73%. BlackRock holds ~11% and Vanguard ~8.6%. Insider ownership by the executive team is in the low single digits.
Recent insider transactions
| Name | Date | Type | Shares | Plan type | Notes |
|---|---|---|---|---|---|
| Andrew Dudum (CEO) | 9 April 2026 | Disposition — gift | 422,933 (×2 gifts = 845,866 total) | Non-sale (gift to trusts) | Estate/trust planning; direct holdings afterwards 887,684 shares |
No open-market discretionary CEO buying has been reported in 2026 to date. The April 9 activity is a gift to trusts (Form 4), not market selling. This is important context: the stock decline from $70 to $14 and back to $28 over 12 months has not been met with visible insider accumulation.
10. Risks and Challenges
- Regulatory / compounding risk. The FDA has active enforcement momentum on mass-marketed compounded GLP-1s. Extending similar actions to testosterone or dermatology compounds would hit margins hard.
- DOJ referral & SEC probe. HHS General Counsel referred Hims to DOJ in February 2026 over the semaglutide pill marketing. An SEC inquiry into disclosures is also reported. Both are open as of 19 April 2026.
- Mix shift on GLP-1. Shifting from ~60–70% gross margin compounded product to ~25–35% branded distribution structurally compresses category gross profit.
- Subscriber growth deceleration. 13% YoY below peer telehealth CAGR.
- Litigation risk. The Novo settlement reserves the right to refile. Other branded manufacturers may litigate.
- Capital structure. $1.0bn convert due 2030; debt-to-equity ~1.8x; dilution risk if the stock recovers to the conversion trigger.
- Key-person risk. Dudum is the face of the company and drives much of the brand messaging.
- Reputational risk. A regulatory enforcement headline cycle weighs on B2C trust in ways that don't show up in quarterly numbers until later.
11. Recent Developments
Last 48 hours
- 17–18 April 2026: Trading around $28 after the 16 April surge on the FDA/HHS peptide review announcement.
- 16 April 2026: HHS Secretary RFK Jr. announces FDA will review de-restriction of 12 peptides; advisory committee meetings scheduled 23–24 July 2026. HIMS closes +13.7%. Bank of America's price target raised to $25 (from $21) — note, we do not use analyst targets in our reports, this is noted only as a factual market event.
Previous 6 months
- 9 March 2026: Novo Nordisk drops patent lawsuit; Hims becomes a preferred D2C distributor of branded Wegovy/Ozempic. Dudum publicly cites 100,000 Wegovy prescriptions per month trajectory.
- 23 February 2026: Q4 / FY2025 earnings — revenue $2.348bn (+59% YoY), adjusted EBITDA $318m, 2.51m subscribers. FY26 guidance set at $2.7–2.9bn revenue and $300–375m adj EBITDA.
- 9 February 2026: Novo Nordisk sues Hims for patent infringement on compounded semaglutide.
- 7 February 2026: Hims withdraws its $49 compounded oral semaglutide pill within 48 hours of its launch.
- 6 February 2026: FDA announces intent to restrict GLP-1 APIs in mass-marketed compounded products; HHS General Counsel refers Hims to DOJ.
- 5 February 2026: Hims launches the $49 compounded oral semaglutide pill.
- Q4 2025: Hers menopause / perimenopause specialty launched; menopause is a stated $1bn 2026 revenue target.
- Q3 2025: Compounded enclomiphene + tadalafil launch; low-testosterone category opens.
- June 2025: ZAVA European acquisition announced (UK, Germany, France, Ireland); Livewell Canada completed later in 2025.
- May 2025: $1.0bn convertible senior notes due 2030 issued. FDA declares semaglutide shortage over — ends legal basis for mass-market semaglutide compounding.
- February 2025: Trybe Labs acquisition (at-home lab testing); peptide manufacturing facility acquired from former CS Bio assets.
12. Key Dates Coming Up
- 11 May 2026 — Q1 2026 earnings release (after close). First post-crisis print; watch Q1 revenue vs $600–625m guide.
- 23–24 July 2026 — FDA Pharmacy Compounding Advisory Committee on peptide Category 2 review. Largest binary catalyst.
- Early August 2026 — Q2 2026 earnings (expected). First full quarter of Novo Wegovy distribution.
- Early November 2026 — Q3 2026 earnings (expected).
Follow our economic calendar for scheduled earnings and macro events, and discuss trade ideas on the ChartsView forum.
Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.
Last Updated: 19 April 2026
Rocket Pharmaceuticals is a US clinical-stage gene therapy company focused on rare diseases, with no approved commercial products. Its lead programme, KRESLADI (marnetegragene autotemcel) for severe Leukocyte Adhesion Deficiency-I, had a PDUFA date of 28 March 2026 that is overdue as of this report with no public FDA action yet disclosed. The pipeline is pivoting to cardiovascular AAV gene therapies for Danon disease, BAG3-associated dilated cardiomyopathy and PKP2-arrhythmogenic cardiomyopathy after a mid-2025 restructuring that cut headcount by ~30% and pushed hematology programmes (Fanconi anemia, pyruvate kinase deficiency) back beyond 2026.
1. Company Snapshot
| Item | Detail |
|---|---|
| Full Name | Rocket Pharmaceuticals, Inc. |
| Ticker | NASDAQ: RCKT |
| Sector / Industry | Biopharmaceutical — Gene Therapy (rare disease) |
| Headquarters | Cranbury, New Jersey, USA |
| CEO & Co-founder | Gaurav Shah, MD |
| Market Cap (mid-April 2026) | ~$378–393 million |
| FY2025 Revenue | ~$0 (pre-commercial) |
| FY2025 Net Loss | $(223.1) million |
| Cash & investments (31 Dec 2025) | $188.9 million |
| Shares outstanding (31 Dec 2025) | 108.3 million |
| Employees | ~202 (post mid-2025 restructuring) |
| Exchange | Nasdaq Global Select |
| Website | rocketpharma.com |
2. Bull Case vs Bear Case
Bull Case
- KRESLADI (LAD-I) BLA resubmission: KRESLADI (LAD-I) BLA resubmission was accepted by FDA in October 2025 with PDUFA 28 March 2026; pivotal Phase 1/2 data showed 100% overall survival at 12 months across all treated patients with no treatment-related serious adverse events.
- Approval would trigger eligibility: Approval would trigger eligibility for a Rare Pediatric Disease Priority Review Voucher, which have recently transacted in the ~$100m range.
- RP-A501 clinical hold was: RP-A501 clinical hold was lifted by the FDA in August 2025; Phase 2 dosing resumption expected in H1 2026 at a recalibrated 3.8 × 10^13 GC/kg dose with sequential 4-week patient intervals; RCKT remains the only clinical-stage gene therapy in Danon disease.
- RP-A601 Phase 1 data: RP-A601 Phase 1 data (May 2025) in PKP2-arrhythmogenic cardiomyopathy showed 110–398% increase in PKP2 protein expression from baseline across three patients and no dose-limiting toxicities at 12-month follow-up; Fast Track (US) and Orphan Drug (US/EU) designations in place.
- Q2 2027 cash runway: Q2 2027 cash runway is guided after ~25% expected operating-expense reduction from the mid-2025 strategic reorganisation; Baker Bros. increased its position in Q1 2026.
Bear Case
- The KRESLADI PDUFA date: The KRESLADI PDUFA date of 28 March 2026 has passed without a public decision as of the date of this report; the drug has previously received one CRL in June 2024 for CMC concerns.
- A patient death from: A patient death from capillary leak syndrome was reported in the Phase 2 Danon trial in May 2025, linked to the novel C3 inhibitor immunosuppression agent; FDA placed and then lifted the clinical hold in August 2025, but the safety overhang remains.
- Stock is down roughly: Stock is down roughly 56% year-on-year, with a 52-week range of $2.19–$8.26 reflecting the June 2024 LAD-I CRL and May 2025 Danon safety event.
- Short interest of 18.6m: Short interest of 18.6m shares as of 31 March 2026 represents ~22.6% of the float; short position rose 26.5% in the second half of March ahead of the PDUFA.
- Recent CEO Form 4 activity: Recent CEO Form 4 activity is net-selling: Gaurav Shah sold shares on 13 and 18 February 2026 and again on 18 November 2025, against a single discretionary purchase of 20,000 shares at $5.08 in April 2025.
3. What Does This Company Actually Do?
Rocket develops ex-vivo and in-vivo gene therapies for rare genetic diseases using two platforms: autologous lentiviral vector (LVV) therapies manufactured in-house at the Cranbury, NJ site, and adeno-associated virus (AAV) therapies primarily for cardiovascular indications. None of the products are approved — the company has essentially no product revenue; operations are funded by equity issuance and partnerships.
LAD-I (KRESLADI, marnetegragene autotemcel). Lentiviral autologous gene therapy for severe Leukocyte Adhesion Deficiency-I, an ultra-rare paediatric immunodeficiency. BLA accepted October 2025; PDUFA 28 March 2026. Previous CRL June 2024 cited CMC issues.
Danon disease (RP-A501). AAV9 gene therapy for a fatal X-linked lysosomal storage disorder affecting the heart. FDA clinical hold imposed May 2025 after a patient death from capillary leak syndrome; hold lifted August 2025 with a modified immunosuppression regimen and recalibrated dose of 3.8 × 10^13 GC/kg.
BAG3-associated dilated cardiomyopathy (RP-A701). AAV gene therapy. IND clearance achieved; first-in-human dosing expected mid-2026.
PKP2-arrhythmogenic cardiomyopathy (RP-A601). AAVrh74 gene therapy; Phase 1 ongoing with three patients at 12-month follow-up. Fast Track (US), Orphan Drug (US/EU).
Deprioritised programmes. RP-L102 (Fanconi anemia, LVV) and RP-L301 (pyruvate kinase deficiency, LVV) remain in Phase 1/2 development but FDA approval is no longer anticipated in 2026 following the mid-2025 portfolio reshuffle.
Note: Rocket Pharmaceuticals is a pre-revenue clinical-stage gene therapy company. The table below reflects the pipeline-value distribution rather than commercial revenue.
| Segment | % of revenue | What it is |
|---|---|---|
| LAD-I / KRESLADI (LVV) | 0% (PDUFA 28 Mar 2026) | Lentiviral autologous gene therapy for severe Leukocyte Adhesion Deficiency-I. BLA accepted October 2025 following a June 2024 CRL over CMC issues. Lead commercial programme. |
| Danon disease / RP-A501 (AAV) | 0% | AAV9 gene therapy for a fatal X-linked lysosomal storage disorder of the heart. FDA clinical hold lifted August 2025 after a patient death; modified immunosuppression regimen at a recalibrated 3.8×10^13 GC/kg dose. |
| BAG3 cardiomyopathy / RP-A701 (AAV) | 0% | AAV gene therapy for BAG3-associated dilated cardiomyopathy. IND clear; first-in-human dosing expected mid-2026. |
| PKP2-ACM / RP-A601 (AAV) | 0% | AAVrh74 gene therapy for PKP2-arrhythmogenic cardiomyopathy. Phase 1 ongoing with three patients at 12-month follow-up; Fast Track (US), Orphan Drug (US/EU). |
| Deprioritised LVV programmes | 0% | RP-L102 (Fanconi anemia) and RP-L301 (pyruvate kinase deficiency) — remain in Phase 1/2 but no longer expected to file for approval in 2026 following the mid-2025 portfolio reshuffle. |
4. The Business Model
Rocket is a pre-revenue biotech. Operating expenses are R&D-heavy with commercial infrastructure being built out in anticipation of a potential KRESLADI launch. Q3 2025 R&D expense was $34.1m and SG&A $18.4m (three-month); this is materially lower than Q2 2025 pre-restructuring levels of $42.7m R&D and $25.0m SG&A. The mid-2025 30% workforce reduction is expected to deliver ~25% operating-expense reduction over 12 months.
Capital is raised through equity issuance, including a recent At-the-Market (ATM) programme. In late March 2026 Rocket sold approximately 19.6m shares via the ATM at $5.11, raising $100m gross proceeds. There is no material debt on the balance sheet.
The eventual commercial model is premium-priced autologous and AAV gene therapies in ultra-rare indications with small but highly concentrated patient populations, supported by direct-to-patient patient-finding and centres-of-excellence treatment networks. Reimbursement in gene therapy remains challenging; sector precedents (BioMarin's Roctavian, CSL's Hemgenix) show lower-than-expected commercial uptake in spite of approval.
5. Financial Health
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenue | ~$0 | ~$0 |
| Net loss | $(258.7)m | $(223.1)m |
| Net loss per share | $(2.73) | $(2.01) |
| Cash, cash equivalents & investments (year-end) | $372.3m | $188.9m |
| Shares outstanding (year-end) | n/a | 108.3m |
FY2025 net loss narrowed to $223.1m from $258.7m in FY2024, reflecting the mid-2025 restructuring. Cash fell from $372.3m at end-2024 to $188.9m at end-2025 as the company funded operations from the balance sheet before the late-March 2026 ATM programme. Management has guided to a runway extending into Q2 2027 after the restructuring and capital raise. Institutional ownership is approximately 98.4% of shares outstanding with holders including RTW Investments, Vanguard, BlackRock, Morgan Stanley, Citigroup, Suvretta, Newtyn and Baker Bros. Advisors.
6. Valuation & Market Data
| Metric | Value | As of |
|---|---|---|
| Share price (trading range) | $3.44–$3.64 | Mid-April 2026 |
| Market cap | ~$378–$393 million | Mid-April 2026 |
| Enterprise value | ~$190 million (cash-adjusted) | Mid-April 2026 |
| Price-to-sales | N/A (no revenue) | — |
| EV/EBITDA (TTM) | N/A (negative EBITDA) | — |
| 52-week high | $8.26 | April 2025 |
| 52-week low | $2.19 | April 2026 |
| YoY price change | -55.86% | As at mid-April 2026 |
| Short interest (shares) | 18.6 million | 31 Mar 2026 |
| Short interest (% float) | ~22.6% | 31 Mar 2026 |
| Days to cover | ~2.9 days | 31 Mar 2026 |
Short interest increased 26.5% between 15 March and 31 March 2026, consistent with positioning into the PDUFA date. Stock is cash-adjusted to roughly $190m EV — a market that is pricing high regulatory risk into the name.
7. What Are They Building / What's Coming?
KRESLADI FDA action. PDUFA date was 28 March 2026; as of this report no public FDA decision has been disclosed. Outcomes are binary: approval, CRL, or further delay.
Danon Phase 2 resumption. The company expects to dose additional patients in the Phase 2 of RP-A501 in H1 2026 at 3.8 × 10^13 GC/kg with a minimum four-week interval between patients. Data presentations are expected at ASGCT in May 2026.
RP-A701 first-in-human dosing. First patient dosing expected mid-2026 in BAG3-DCM Phase 1.
RP-A601 ongoing. Additional patients and longer follow-up expected through 2026 in PKP2-ACM Phase 1.
Management statements from Q4 2025 call (26 February 2026). Gaurav Shah described Rocket as "positioned at the intersection of cardiovascular disease and gene therapy" with "more than five years of clinical experience in Danon disease". Strategic focus is now on three cardiovascular programmes; hematology programmes (Fanconi anemia, PKD) have been explicitly deprioritised and approvals for both are no longer expected in 2026.
8. Competitive Landscape
Rocket's lead indications sit in niches with few direct rivals, making platform peers more relevant than same-indication competitors.
Same-indication competition. LAD-I — Rocket's KRESLADI would be the first approved gene therapy; no approved competitor exists, but the market is very small (hundreds of patients globally). Danon disease — no approved competitor; Rocket is first-in-class. BAG3-DCM and PKP2-ACM — no approved gene therapies in cardiovascular indications; field is emerging.
Platform / sector peers. Sarepta Therapeutics (Elevidys for DMD) is pivoting after a 2025 safety crisis that halted several AAV programmes following three patient deaths from liver failure. BioMarin (Roctavian for haemophilia A) has seen commercially disappointing uptake. CSL / uniQure (Hemgenix for haemophilia B) — similar slow commercial trajectory. bluebird bio — effectively wound down. Beam Therapeutics and Prime Medicine compete at the next generation (base / prime editing) rather than classical AAV/LVV.
| Peer | Market cap (Apr 2026) | Notable capex / KPI |
|---|---|---|
| Sarepta Therapeutics (SRPT) | ~$4bn | Elevidys ~$900m FY25 revenue; 2025 AAV safety crisis |
| BioMarin Pharmaceutical (BMRN) | ~$12bn | Roctavian uptake <$50m annualised |
| CSL Ltd / uniQure (CSL.AX / QURE) | ~$80bn / ~$600m | Hemgenix (haemophilia B) revenue ramp slow |
| Beam Therapeutics (BEAM) | ~$2bn | Multiple base-editing INDs filed 2024–25 |
| Prime Medicine (PRME) | ~$300m | Prime-editing preclinical pipeline |
9. Leadership and Ownership
Gaurav Shah, MD — Co-founder and CEO. Previously Global Program Head, Cell & Gene Therapies, Novartis; hematology/oncology fellowship at Memorial Sloan Kettering; MD from Columbia (AOA); undergraduate at Harvard (summa cum laude).
Aaron Ondrey — Chief Financial Officer. Previously CFO at Mirati Therapeutics.
Kinnari Patel, PharmD, MBA — President, Head of R&D and COO.
Sarbani Chaudhuri — Chief Commercial & Medical Affairs Officer. Previously VP Hematology at J&J Innovative Medicine.
Roderick Wong, MD — Chair of the Board (founder/managing partner of RTW Investments).
Ownership. Institutional holders own approximately 98.4% of shares. Top holders include RTW Investments LP, Vanguard, BlackRock, Morgan Stanley, Citigroup, Suvretta Capital, Newtyn Management and Baker Bros. Advisors. Baker Bros. raised its position in Q1 2026 to approximately 1.1m shares, adding roughly 1m shares at ~$7.30.
Recent insider transactions (SEC Form 4).
| Name | Date | Type | Shares | Price | Value | Plan |
|---|---|---|---|---|---|---|
| Gaurav Shah (CEO) | 18 Feb 2026 | Sell (tax withholding) | 5,990 | $3.34 | ~$20.0k | RSU-related |
| Gaurav Shah (CEO) | 13 Feb 2026 | Sell | 12,279 | $3.31 | ~$40.6k | Discretionary |
| Gaurav Shah (CEO) | 18 Nov 2025 | Sell | 6,276 | $2.98 | ~$18.7k | Discretionary |
| Gaurav Shah (CEO) | 20 May 2025 | Sell | 2,253 | $6.45 | ~$14.5k | Discretionary |
| Gaurav Shah (CEO) | 10 Apr 2025 | Buy | 20,000 | $5.08 | ~$101.6k | Discretionary (open-market) |
On a 12-month view the CEO has been a net seller, with one notable open-market discretionary purchase in April 2025 at $5.08 — close to current market levels.
10. Risks and Challenges
Regulatory. KRESLADI's PDUFA date of 28 March 2026 has passed with no public outcome, exposing shareholders to a possible second CRL or further delay. Any adverse outcome on RP-A501 (Danon) safety monitoring could result in another clinical hold.
Clinical. The May 2025 patient death tied to capillary leak syndrome with a novel C3 inhibitor immunosuppression agent is a material historical safety signal. Gene-therapy field-wide, the 2025 Sarepta events have raised the FDA bar for AAV product safety.
Cash burn and dilution. Runway into Q2 2027 is sensitive to approval timing and commercial ramp assumptions; ATM issuance and potential future offerings imply further dilution. Share count and net loss per share trends need monitoring through Q1 2026 earnings.
Commercial execution. Rocket has no commercial experience; gene-therapy pricing and reimbursement remain difficult. Addressable markets for LAD-I and Danon are small, amplifying the importance of every patient identified and reimbursed.
Competitive and technological. AAV platform sentiment is impaired following Sarepta events; CRISPR-based competitors could reach some of Rocket's target indications.
Concentration. Near-term value is highly concentrated in KRESLADI approval and RP-A501 execution. Operational disruption at the Cranbury LVV facility would be disproportionate given in-house manufacturing dependence.
11. Recent Developments
- Last 48 hours (17–19 April 2026): — No material company-specific announcements detected. Market remains focused on the overdue KRESLADI PDUFA decision.
- April 2026. — ATM offering of ~19.6m shares at $5.11 for $100m gross proceeds completed in late March / early April per prospectus filing. Short interest updated 16 April showing 22.6% of float short as of 31 March 2026. No FDA decision on KRESLADI has been publicly disclosed as at the date of this report.
- February 2026. — Q4 2025 and full-year 2025 earnings released 26 February: FY2025 net loss $(223.1)m, cash $188.9m, runway guided into Q2 2027. Management confirmed focus on Danon, BAG3-DCM and PKP2-ACM; Fanconi anemia and PKD programmes deprioritised. CEO sold small amounts of stock on 13 and 18 February.
- October 2025. — FDA accepted resubmission of the KRESLADI BLA; PDUFA date set to 28 March 2026.
- August 2025. — FDA lifted the clinical hold on the RP-A501 Phase 2 Danon trial (imposed in May 2025 following a patient death) with a modified immunosuppression protocol and recalibrated dose (3.8 × 10^13 GC/kg) with four-week intervals between sequential patient dosings.
- May 2025. — One patient in the RP-A501 Phase 2 died following capillary leak syndrome associated with a novel C3 inhibitor immunosuppression agent; a second patient showed early capillary leak signs but recovered after a reduced course. FDA placed a clinical hold.
- June 2024. — FDA issued a CRL for the first KRESLADI BLA submission citing CMC concerns.
12. Key Dates Coming Up
- Imminent: KRESLADI (LAD-I) FDA action — PDUFA was 28 March 2026 and remains outstanding as at the date of this report.
- H1 2026: RP-A501 Phase 2 additional patient dosing resumption.
- May 2026: ASGCT 28th Annual Meeting — gene therapy data presentations (RP-A501, pipeline updates).
- Mid-2026: RP-A701 (BAG3-DCM) Phase 1 first-in-human dosing.
- May 2026 (approx): Q1 2026 earnings release — refreshed cash burn and runway update.
- Q2 2027: Guided cash runway — financing required beyond this point absent a material monetising event.
- December 2026: ASH Annual Meeting — potential hematology programme data.
Track RCKT on the ChartsView Live Charts, check biotech catalysts on the Economic Calendar, discuss positioning in the Forum, and see more company research on the Blog.
Disclaimer
This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.